Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

Alba A. Brandes; E. Franceschi; Thierry Gorlia; Wolfgang Wick; A. H. Jacobs; B. G. Baumert; Martin J. van den Bent; C.M. Weller; Roger Stupp

doi:10.1016/j.ejca.2011.10.027

Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

Alba A. Brandes, E. Franceschi, Thierry Gorlia, Wolfgang Wick, A. H. Jacobs, B. G. Baumert, Martin J. van den Bent, C.M. Weller, Roger Stupp

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	896-903
Journal	European Journal of Cancer
Volume	48
Issue number	6
DOIs	https://doi.org/10.1016/j.ejca.2011.10.027
Publication status	Published - Apr 2012

Keywords

Recurrent glioblastoma
End-points
Overall survival
Progression-free survival
Overall survival rates

Access to Document

10.1016/j.ejca.2011.10.027

Cite this

Brandes, A. A., Franceschi, E., Gorlia, T., Wick, W., Jacobs, A. H., Baumert, B. G., van den Bent, M. J., Weller, C. M., & Stupp, R. (2012). Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. European Journal of Cancer, 48(6), 896-903. https://doi.org/10.1016/j.ejca.2011.10.027

Brandes, Alba A. ; Franceschi, E. ; Gorlia, Thierry ; Wick, Wolfgang ; Jacobs, A. H. ; Baumert, B. G. ; van den Bent, Martin J. ; Weller, C.M. ; Stupp, Roger. / Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. In: European Journal of Cancer. 2012 ; Vol. 48, No. 6. pp. 896-903.

@article{af283601bc9b4ee2a88b46d080c56b43,

title = "Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma",

keywords = "Recurrent glioblastoma, End-points, Overall survival, Progression-free survival, Overall survival rates",

author = "Brandes, {Alba A.} and E. Franceschi and Thierry Gorlia and Wolfgang Wick and Jacobs, {A. H.} and Baumert, {B. G.} and {van den Bent}, {Martin J.} and C.M. Weller and Roger Stupp",

year = "2012",

month = apr,

doi = "10.1016/j.ejca.2011.10.027",

language = "English",

volume = "48",

pages = "896--903",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

number = "6",

}

Brandes, AA, Franceschi, E, Gorlia, T, Wick, W, Jacobs, AH, Baumert, BG, van den Bent, MJ, Weller, CM & Stupp, R 2012, 'Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma', European Journal of Cancer, vol. 48, no. 6, pp. 896-903. https://doi.org/10.1016/j.ejca.2011.10.027

Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. / Brandes, Alba A.; Franceschi, E.; Gorlia, Thierry; Wick, Wolfgang; Jacobs, A. H.; Baumert, B. G.; van den Bent, Martin J.; Weller, C.M.; Stupp, Roger.

In: European Journal of Cancer, Vol. 48, No. 6, 04.2012, p. 896-903.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

AU - Brandes, Alba A.

AU - Franceschi, E.

AU - Gorlia, Thierry

AU - Wick, Wolfgang

AU - Jacobs, A. H.

AU - Baumert, B. G.

AU - van den Bent, Martin J.

AU - Weller, C.M.

AU - Stupp, Roger

PY - 2012/4

Y1 - 2012/4

KW - Recurrent glioblastoma

KW - End-points

KW - Overall survival

KW - Progression-free survival

KW - Overall survival rates

U2 - 10.1016/j.ejca.2011.10.027

DO - 10.1016/j.ejca.2011.10.027

M3 - Article

VL - 48

SP - 896

EP - 903

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -